Global Lung Cancer Liquid Biopsy Market 2017-2021

肺がん用液体細胞診の世界市場2017-2021:CTC・ctDNA、エキソソーム・RNA

◆タイトル:Global Lung Cancer Liquid Biopsy Market 2017-2021
◆商品コード:IRTNTR15752
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年11月24日
◆ページ数:109
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、肺がん用液体細胞診の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、肺がん用液体細胞診の世界市場規模及び予測、製品別分析、需要先別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は肺がん用液体細胞診の世界市場が2017-2021年期間中に年平均17.15%成長すると予測しています。当レポート上に記載されている主な企業は、Biocept、Exosome Diagnostics、F. Hoffmann-La Roche、QIAGEN等です。

・エグゼクティブサマリー
・肺がん用液体細胞診の世界市場:市場概観
・肺がん用液体細胞診の世界市場:業界の構造分析
・肺がん用液体細胞診の世界市場:市場規模及び予測
・肺がん用液体細胞診の世界市場:製品別分析
・肺がん用液体細胞診の世界市場:需要先別分析
・肺がん用液体細胞診の世界市場:地域別分析
・肺がん用液体細胞診の世界市場:アジア市場規模
・肺がん用液体細胞診の世界市場:アメリカ市場規模
・肺がん用液体細胞診の世界市場:ヨーロッパ市場規模
・肺がん用液体細胞診の世界市場:成長要因
・肺がん用液体細胞診の世界市場:課題
・肺がん用液体細胞診の世界市場:市場動向
・肺がん用液体細胞診の世界市場:競争状況
・肺がん用液体細胞診の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Lung Cancer Liquid Biopsy
A liquid biopsy helps to identify free-floating tumor DNA (also known as circulating DNA) within the blood sample of a patient. Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. It is observed that the use of a liquid biopsy to identify carcinogenic cells of lungs will help in the early diagnosis of lung cancer.

Technavio’s analysts forecast the global lung cancer liquid biopsy market to grow at a CAGR of 17.15% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global lung cancer liquid biopsy market for 2017-2021. To calculate the market size, the report considers the sales and values of lung cancer liquid biopsy assays.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Lung Cancer Liquid Biopsy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Biocept
• Exosome Diagnostics
• F. Hoffmann-La Roche
• QIAGEN

[Other prominent vendors]
• AccuraGen
• Agena Bioscience
• BARD1
• BGI
• Biodesix
• Bio-Rad Laboratories
• Cancer Genetics
• CellMax Life
• Circulogene
• CLEARBRIDGE BIOMEDICS
• Cynvenio Biosystems
• EntroGen
• Epic Sciences
• Epigenomics
• Fluxion Biosciences
• Freenome
• Gencurix
• Genetracer Biotech
• Genomic Health
• Grail
• Guardant Health
• HeliTec
• Inivata
• Lonza
• MedGenome
• Nanoview Diagnostics
• Natera
• Novogene
• OncoCyte
• OncoDNA
• Pathway Genomics
• Personal Genome Diagnostics
• Predicine
• Shuwen Biotech
• Sysmex
• Thermo Fisher Scientific
• Transgenomic
• Trovagene

[Market driver]
• Rising incidence of lung cancer
• For a full, detailed list, view our report

[Market challenge]
• High cost of lab testing procedure
• For a full, detailed list, view our report

[Market trend]
• Vendors’ focus on clinical trials
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing 2016
• Market size and forecast 2016-2021

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY PRODUCT
• Segmentation by product
• Comparison by product
• Global lung cancer liquid biopsy market by CTCs and ctDNA
• Global lung cancer liquid biopsy market by exosomes and RNA
• Market opportunity by product

PART 09: MARKET SEGMENTATION BY END-USER
• Segmentation by end-user
• Market share by end-user
• Clinical diagnostic laboratories
• Hospitals and clinics
• Physicians’ office laboratories

PART 10: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Lung cancer liquid biopsy market in Americas
• Lung cancer liquid biopsy market in EMEA
• Lung cancer liquid biopsy market in APAC
• Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 13: MARKET TRENDS
• Growing partnership agreements
• Vendors’ focus on clinical trials
• Application of liquid biopsy for personalized treatment

PART 14: VENDOR LANDSCAPE
• Competitive landscape

PART 15: KEY VENDOR ANALYSIS
• Biocept
• Exosome Diagnostics
• F. Hoffmann-La Roche
• QIAGEN
• Key companies to watch
• Other prominent vendors

PART 16: APPENDIX
• List of abbreviations

[List of Exhibits]
Exhibit 01: Overview of tissue biopsy and liquid biopsy used for detection of lung cancer
Exhibit 02: Parent market
Exhibit 03: Market segments
Exhibit 04: Market size 2016
Exhibit 05: Global lung cancer liquid biopsy market 2016-2021 ($ millions)
Exhibit 06: Global lung cancer liquid biopsy market: Year-over-year growth 2017-2021 (%)
Exhibit 07: Five forces analysis
Exhibit 08: Global lung cancer liquid biopsy market by product 2016-2021 (%)
Exhibit 09: Comparison by product
Exhibit 10: Global lung cancer liquid biopsy market by CTCs and ctDNA: Market overview
Exhibit 11: Global lung cancer liquid biopsy market by CTCs and ctDNA 2016-2021 ($ millions)
Exhibit 12: Global lung cancer liquid biopsy market by CTCs and ctDNA: Year-over-year growth 2017-2021 (%)
Exhibit 13: Global lung cancer liquid biopsy market by exosomes and RNA: Market overview
Exhibit 14: Global lung cancer liquid biopsy market by exosomes and RNA 2016-2021 ($ millions)
Exhibit 15: Global lung cancer liquid biopsy market by exosomes and RNA: Year-over-year growth 2017-2021 (%)
Exhibit 16: Market opportunity by product
Exhibit 17: Market share by end-user
Exhibit 18: Global lung cancer liquid biopsy market by end-users 2016: Market overview
Exhibit 19: Global lung cancer liquid biopsy market by geography 2016-2021 (%)
Exhibit 20: Regional comparison
Exhibit 21: Lung cancer liquid biopsy market in Americas 2016-2021 ($ millions)
Exhibit 22: Lung cancer liquid biopsy market in Americas: Year-over-year growth 2017-2021 (%)
Exhibit 23: Top 3 countries in Americas
Exhibit 24: Lung cancer liquid biopsy market in EMEA 2016-2021 ($ millions)
Exhibit 25: Lung cancer liquid biopsy market in EMEA: Year-over-year growth 2017-2021 (%)
Exhibit 26: Top 3 countries in EMEA
Exhibit 27: Lung cancer liquid biopsy market in APAC 2016-2021 ($ millions)
Exhibit 28: Lung cancer liquid biopsy market in APAC: Year-over-year growth 2017-2021 (%)
Exhibit 29: Top 3 countries in APAC
Exhibit 30: Addressable market of lung cancer 2016
Exhibit 31: Limitations associated with the application of lung cancer liquid biopsy
Exhibit 32: Competitive structure analysis of global lung cancer liquid biopsy market 2016
Exhibit 33: Strategic success factors of companies in global lung cancer liquid biopsy market 2016
Exhibit 34: Biocept: Key highlights
Exhibit 35: Biocept: Strength assessment
Exhibit 36: Biocept: Strategy assessment
Exhibit 37: Biocept: Opportunity assessment
Exhibit 38: Exosome Diagnostics: Key highlights
Exhibit 39: Exosome Diagnostics: Strength assessment
Exhibit 40: Exosome Diagnostics: Strategy assessment
Exhibit 41: Exosome Diagnostics: Opportunity assessment
Exhibit 42: F. Hoffmann-La Roche: Key highlights
Exhibit 43: F. Hoffmann-La Roche: Strength assessment
Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
Exhibit 45: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 46: QIAGEN: Key highlights
Exhibit 47: QIAGEN: Strength assessment
Exhibit 48: QIAGEN: Strategy assessment
Exhibit 49: QIAGEN: Opportunity assessment
Exhibit 50: Biocartis: Company assessment
Exhibit 51: Siemens Healthcare: Company assessment
Exhibit 52: Global lung cancer liquid biopsy market: Other prominent vendors



【掲載企業】

Biocept, Exosome Diagnostics, F. Hoffmann-La Roche, and QIAGEN, AccuraGen, Agena Bioscience, BARD1, BGI, Biodesix, Bio-Rad Laboratories, Cancer Genetics, CellMax Life, Circulogene, CLEARBRIDGE BIOMEDICS, Cynvenio Biosystems, EntroGen, Epic Sciences, Epigenomics, Fluxion Biosciences, Freenome, Gencurix, Genetracer Biotech, Genomic Health, Grail, Guardant Health, HeliTec, Inivata, Lonza, MedGenome, Nanoview Diagnostics, Natera, Novogene, OncoCyte, OncoDNA, Pathway Genomics, Personal Genome Diagnostics, Predicine, Shuwen Biotech, Sysmex, Thermo Fisher Scientific, Transgenomic, and Trovagene.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[肺がん用液体細胞診の世界市場2017-2021:CTC・ctDNA、エキソソーム・RNA]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆